MedTrace Logo

Phase II / III Study of COVID-19 DNA Vaccine (AG0302-COVID19)

NCT04655625 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2022-06-08

No results posted yet for this study

Summary

This study will assess the safety, immunogenicity and efficacy of AG0302-COVID19 in healthy adult volunteers.

Conditions

Interventions

BIOLOGICAL

Group A (AG0302-COVID19)

2 mg of AG0302-COVID19 twice at 2-week intervals

BIOLOGICAL

Group A (Placebo)

Placebo twice at 2-week intervals

BIOLOGICAL

Group B (AG0302-COVID19)

2 mg of AG0302-COVID19 twice at 4-week intervals

BIOLOGICAL

Group B (Placebo)

Placebo twice at 4-week intervals

Sponsors & Collaborators

  • Japan Agency for Medical Research and Development

    collaborator OTHER_GOV

  • AnGes, Inc.

    lead INDUSTRY

Principal Investigators

  • AnGes, Inc. Clinical Development · AnGes, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-11-23
Primary Completion
2021-04-02
Completion
2022-02-01

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04655625 on ClinicalTrials.gov